Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer
Abstract Purpose. A clinical feasibility study using a removable prostate stent as fiducial for image-guided radiotherapy (IGRT) of localized prostate cancer (PC). Material and methods. The study included patients with local or locally advanced PC. The clinical target volume (CTV) was outlined on ma...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 2011-05, Vol.50 (4), p.547-554 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 554 |
|---|---|
| container_issue | 4 |
| container_start_page | 547 |
| container_title | Acta oncologica |
| container_volume | 50 |
| creator | Carl, Jesper Nielsen, Jane Holmberg, Mats Larsen, Erik Hoejkjaer Fabrin, Knud Fisker, Rune V. |
| description | Abstract
Purpose. A clinical feasibility study using a removable prostate stent as fiducial for image-guided radiotherapy (IGRT) of localized prostate cancer (PC). Material and methods. The study included patients with local or locally advanced PC. The clinical target volume (CTV) was outlined on magnetic resonance (MR) images co-registered to planning computer tomography (CT) images. Daily online IGRT was delivered using the stent as fiducial. Risk of migration was estimated using multiple MR. Acute urinary toxicity was scored using the international prostate symptom score (IPSS). Late gastro-intestinal (GI) and genito-urinary (GU) toxicity was scored using the Radio Therapy Oncology Group (RTOG) score, biochemical failure (BF) was defined as an elevation of prostate specific antigen (PSA) above nadir plus 2 ng/ml after radiotherapy. Results. One hundred men were enrolled in the study. Ninety completed radiotherapy with the stent as fiducial. No migration of the stent was seen, but three cases of dislocation of the stent to the bladder were observed. Acute urinary toxicity based on IPSS was comparable to toxicity in patients who had gold markers (GM) as fiducials. Removal of the stent was associated with a high frequency of urinary retention. Late GI and GU toxicity and BF were comparable to those of other studies, but longer observation time is needed. Conclusions. This study reports the first clinical results of using a prostate stent as fiducial. No migration of the stent observed. Dislocation of the stent to the urinary bladder was observed in three cases, requiring removal of the stent and insertion of a new fiducial. Acute toxicity during radiotherapy evaluated from IPSS was comparable to toxicity in patients with GM. Removal of the stent was associated with a high frequency of post procedural urinary retention. Late toxicity and BF were comparable to those of other studies, though longer observation time is needed. |
| doi_str_mv | 10.3109/0284186X.2010.541935 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_0284186X_2010_541935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_0284186X_2010_541935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-574421bb0b46fa2ca63f7fc733d29251c142d496a6dd2f434af883a50e67a893</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlbfQCQvMJr7zGwEKd6g4KaL7oYzmYSmzI0ks-jbm6FWcOPqwOH7z8_5ELqn5JFTUj4RVghaqN0jI2klBS25vEBLqiTNGFO7S7SckWxmFugmhAMhhPFcXqMFozQXkpElgnXreqehxd6EqY0BWz902DofIp6CwYPFox9ChGhwiKaPGBLjmkm7FLKDxx4aN8S98TAe_-Aaem38Lbqy0AZz9zNXaPv2ul1_ZJuv98_1yybTXNGYyVwIRuua1EJZYBoUt7nVOecNK5mkmgrWiFKBahpmBRdgi4KDJEblUJR8hcTprE71wRtbjd514I8VJdUsrDoLq2Zh1UlYij2cYuNUd6b5DZ0NJeD5BLg-PdvB3kAb9xq8qQ7D5Pv00v8N31Uqe18</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Taylor & Francis Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Carl, Jesper ; Nielsen, Jane ; Holmberg, Mats ; Larsen, Erik Hoejkjaer ; Fabrin, Knud ; Fisker, Rune V.</creator><creatorcontrib>Carl, Jesper ; Nielsen, Jane ; Holmberg, Mats ; Larsen, Erik Hoejkjaer ; Fabrin, Knud ; Fisker, Rune V.</creatorcontrib><description>Abstract
Purpose. A clinical feasibility study using a removable prostate stent as fiducial for image-guided radiotherapy (IGRT) of localized prostate cancer (PC). Material and methods. The study included patients with local or locally advanced PC. The clinical target volume (CTV) was outlined on magnetic resonance (MR) images co-registered to planning computer tomography (CT) images. Daily online IGRT was delivered using the stent as fiducial. Risk of migration was estimated using multiple MR. Acute urinary toxicity was scored using the international prostate symptom score (IPSS). Late gastro-intestinal (GI) and genito-urinary (GU) toxicity was scored using the Radio Therapy Oncology Group (RTOG) score, biochemical failure (BF) was defined as an elevation of prostate specific antigen (PSA) above nadir plus 2 ng/ml after radiotherapy. Results. One hundred men were enrolled in the study. Ninety completed radiotherapy with the stent as fiducial. No migration of the stent was seen, but three cases of dislocation of the stent to the bladder were observed. Acute urinary toxicity based on IPSS was comparable to toxicity in patients who had gold markers (GM) as fiducials. Removal of the stent was associated with a high frequency of urinary retention. Late GI and GU toxicity and BF were comparable to those of other studies, but longer observation time is needed. Conclusions. This study reports the first clinical results of using a prostate stent as fiducial. No migration of the stent observed. Dislocation of the stent to the urinary bladder was observed in three cases, requiring removal of the stent and insertion of a new fiducial. Acute toxicity during radiotherapy evaluated from IPSS was comparable to toxicity in patients with GM. Removal of the stent was associated with a high frequency of post procedural urinary retention. Late toxicity and BF were comparable to those of other studies, though longer observation time is needed.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/0284186X.2010.541935</identifier><identifier>PMID: 21174520</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Aged ; Feasibility Studies ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Prognosis ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - radiotherapy ; Radiotherapy Planning, Computer-Assisted ; Stents ; Tomography, X-Ray Computed</subject><ispartof>Acta oncologica, 2011-05, Vol.50 (4), p.547-554</ispartof><rights>2011 Informa Healthcare 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-574421bb0b46fa2ca63f7fc733d29251c142d496a6dd2f434af883a50e67a893</citedby><cites>FETCH-LOGICAL-c361t-574421bb0b46fa2ca63f7fc733d29251c142d496a6dd2f434af883a50e67a893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/0284186X.2010.541935$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/0284186X.2010.541935$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21174520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carl, Jesper</creatorcontrib><creatorcontrib>Nielsen, Jane</creatorcontrib><creatorcontrib>Holmberg, Mats</creatorcontrib><creatorcontrib>Larsen, Erik Hoejkjaer</creatorcontrib><creatorcontrib>Fabrin, Knud</creatorcontrib><creatorcontrib>Fisker, Rune V.</creatorcontrib><title>Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Abstract
Purpose. A clinical feasibility study using a removable prostate stent as fiducial for image-guided radiotherapy (IGRT) of localized prostate cancer (PC). Material and methods. The study included patients with local or locally advanced PC. The clinical target volume (CTV) was outlined on magnetic resonance (MR) images co-registered to planning computer tomography (CT) images. Daily online IGRT was delivered using the stent as fiducial. Risk of migration was estimated using multiple MR. Acute urinary toxicity was scored using the international prostate symptom score (IPSS). Late gastro-intestinal (GI) and genito-urinary (GU) toxicity was scored using the Radio Therapy Oncology Group (RTOG) score, biochemical failure (BF) was defined as an elevation of prostate specific antigen (PSA) above nadir plus 2 ng/ml after radiotherapy. Results. One hundred men were enrolled in the study. Ninety completed radiotherapy with the stent as fiducial. No migration of the stent was seen, but three cases of dislocation of the stent to the bladder were observed. Acute urinary toxicity based on IPSS was comparable to toxicity in patients who had gold markers (GM) as fiducials. Removal of the stent was associated with a high frequency of urinary retention. Late GI and GU toxicity and BF were comparable to those of other studies, but longer observation time is needed. Conclusions. This study reports the first clinical results of using a prostate stent as fiducial. No migration of the stent observed. Dislocation of the stent to the urinary bladder was observed in three cases, requiring removal of the stent and insertion of a new fiducial. Acute toxicity during radiotherapy evaluated from IPSS was comparable to toxicity in patients with GM. Removal of the stent was associated with a high frequency of post procedural urinary retention. Late toxicity and BF were comparable to those of other studies, though longer observation time is needed.</description><subject>Aged</subject><subject>Feasibility Studies</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiotherapy Planning, Computer-Assisted</subject><subject>Stents</subject><subject>Tomography, X-Ray Computed</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotlbfQCQvMJr7zGwEKd6g4KaL7oYzmYSmzI0ks-jbm6FWcOPqwOH7z8_5ELqn5JFTUj4RVghaqN0jI2klBS25vEBLqiTNGFO7S7SckWxmFugmhAMhhPFcXqMFozQXkpElgnXreqehxd6EqY0BWz902DofIp6CwYPFox9ChGhwiKaPGBLjmkm7FLKDxx4aN8S98TAe_-Aaem38Lbqy0AZz9zNXaPv2ul1_ZJuv98_1yybTXNGYyVwIRuua1EJZYBoUt7nVOecNK5mkmgrWiFKBahpmBRdgi4KDJEblUJR8hcTprE71wRtbjd514I8VJdUsrDoLq2Zh1UlYij2cYuNUd6b5DZ0NJeD5BLg-PdvB3kAb9xq8qQ7D5Pv00v8N31Uqe18</recordid><startdate>201105</startdate><enddate>201105</enddate><creator>Carl, Jesper</creator><creator>Nielsen, Jane</creator><creator>Holmberg, Mats</creator><creator>Larsen, Erik Hoejkjaer</creator><creator>Fabrin, Knud</creator><creator>Fisker, Rune V.</creator><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201105</creationdate><title>Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer</title><author>Carl, Jesper ; Nielsen, Jane ; Holmberg, Mats ; Larsen, Erik Hoejkjaer ; Fabrin, Knud ; Fisker, Rune V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-574421bb0b46fa2ca63f7fc733d29251c142d496a6dd2f434af883a50e67a893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Feasibility Studies</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiotherapy Planning, Computer-Assisted</topic><topic>Stents</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carl, Jesper</creatorcontrib><creatorcontrib>Nielsen, Jane</creatorcontrib><creatorcontrib>Holmberg, Mats</creatorcontrib><creatorcontrib>Larsen, Erik Hoejkjaer</creatorcontrib><creatorcontrib>Fabrin, Knud</creatorcontrib><creatorcontrib>Fisker, Rune V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carl, Jesper</au><au>Nielsen, Jane</au><au>Holmberg, Mats</au><au>Larsen, Erik Hoejkjaer</au><au>Fabrin, Knud</au><au>Fisker, Rune V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2011-05</date><risdate>2011</risdate><volume>50</volume><issue>4</issue><spage>547</spage><epage>554</epage><pages>547-554</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>Abstract
Purpose. A clinical feasibility study using a removable prostate stent as fiducial for image-guided radiotherapy (IGRT) of localized prostate cancer (PC). Material and methods. The study included patients with local or locally advanced PC. The clinical target volume (CTV) was outlined on magnetic resonance (MR) images co-registered to planning computer tomography (CT) images. Daily online IGRT was delivered using the stent as fiducial. Risk of migration was estimated using multiple MR. Acute urinary toxicity was scored using the international prostate symptom score (IPSS). Late gastro-intestinal (GI) and genito-urinary (GU) toxicity was scored using the Radio Therapy Oncology Group (RTOG) score, biochemical failure (BF) was defined as an elevation of prostate specific antigen (PSA) above nadir plus 2 ng/ml after radiotherapy. Results. One hundred men were enrolled in the study. Ninety completed radiotherapy with the stent as fiducial. No migration of the stent was seen, but three cases of dislocation of the stent to the bladder were observed. Acute urinary toxicity based on IPSS was comparable to toxicity in patients who had gold markers (GM) as fiducials. Removal of the stent was associated with a high frequency of urinary retention. Late GI and GU toxicity and BF were comparable to those of other studies, but longer observation time is needed. Conclusions. This study reports the first clinical results of using a prostate stent as fiducial. No migration of the stent observed. Dislocation of the stent to the urinary bladder was observed in three cases, requiring removal of the stent and insertion of a new fiducial. Acute toxicity during radiotherapy evaluated from IPSS was comparable to toxicity in patients with GM. Removal of the stent was associated with a high frequency of post procedural urinary retention. Late toxicity and BF were comparable to those of other studies, though longer observation time is needed.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>21174520</pmid><doi>10.3109/0284186X.2010.541935</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 2011-05, Vol.50 (4), p.547-554 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_0284186X_2010_541935 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Taylor & Francis Journals Complete; Alma/SFX Local Collection |
| subjects | Aged Feasibility Studies Humans Magnetic Resonance Imaging Male Middle Aged Prognosis Prostatic Neoplasms - diagnosis Prostatic Neoplasms - radiotherapy Radiotherapy Planning, Computer-Assisted Stents Tomography, X-Ray Computed |
| title | Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A08%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20results%20from%20first%20use%20of%20prostate%20stent%20as%20fiducial%20for%20radiotherapy%20of%20prostate%20cancer&rft.jtitle=Acta%20oncologica&rft.au=Carl,%20Jesper&rft.date=2011-05&rft.volume=50&rft.issue=4&rft.spage=547&rft.epage=554&rft.pages=547-554&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.3109/0284186X.2010.541935&rft_dat=%3Cinformahealthcare_cross%3E10_3109_0284186X_2010_541935%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21174520&rfr_iscdi=true |